Alzheimer’s disease prevented by pharmacological chaperone therapy in mice
Pharmacological chaperones have proved successful in mediating the activity of VPS35 in mice models of Alzheimer’s disease – resulting in a reduction of tau and amyloid beta aggregates when compared to untreated mice.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>